Click to view the official SEC document.

YouTube video by CASIOPEA - Topic

YouTube video by Legal AF

Cellectar Biosciences (NASDAQ:CLRB) has partnered with Evestia Clinical to conduct a Phase 1b clinical trial for CLR 125, an iodine-125 Auger-emitting drug candidate targeting triple-negative breast cancer (TNBC). The trial is set to begin in Q4 2025 at Mayo Clinic, with Dr. Pooja Advani serving as lead investigator.Evestia Clinical, recently merged with Atlantic Research Group (ARG), will provide comprehensive CRO services, leveraging their experience from over 300 oncology studies. CLR 125 is being developed to treat various solid tumors, including triple negative breast, lung, and colorectal cancers.

Click to view the official SEC document.

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)

Cellectar Biosciences (NASDAQ: CLRB) will report its second quarter 2026 financial results and provide a corporate update on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time. The event will include a conference call and webcast, with a replay available on the company’s Investor Relations Events page.

YouTube video by GriffinMind

Cellectar Biosciences (NASDAQ: CLRB) reported publication of a Phase 1 dose-escalation study of iopofosine I 131 plus low-dose dexamethasone in 31 heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers.Among 26 efficacy-evaluable patients, 84.6% achieved stable disease or better. The overall response rate (ORR) was 15.4%, including four partial responses, and a subgroup of evaluable patients (n=10) receiving at least 60 mCi showed a 30% ORR. Investigators described a favorable, manageable safety profile, with adverse events mainly predictable, reversible hematologic toxicities and generally low-grade non-hematologic events, and no new safety signals. According to Cellectar, these findings support continued development of iopofosine I 131 as a novel targeted radiotherapeutic across multiple B‑cell malignancies and suggest potential for repeat dosing strategies.